New drug SKB571 targets advanced lung cancer in Mid-Stage trial

NCT ID NCT07230405

Recruiting now Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests a new drug called SKB571 in 295 people with advanced non-small cell lung cancer. The drug is given every three weeks to see if it can shrink tumors and how safe it is. The goal is to find a better treatment option for this serious disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB571
What this could lead to: If successful, this could point toward a new treatment option for advanced non-small cell lung cancer.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. Side effects are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NON-SMALL CELL)

Contacts and locations

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Sun Yat-Sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.